{"preliminary_commentary":{"by_channel":{"youtube":7,"podcast":3,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06337318\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"S2308","nct_id":"NCT06337318","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=s2308-nct06337318. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive rituximab IV on day 1 of cycle 1 and receive rituximab and hyaluronidase SC on days 8, 15 and 22 of cycle 1 and SC on day 1 of subsequent cycles. Cycles repeat every 56 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.","label":"Arm I (Rituximab, rituximab and hyaluronidase)","type":"EXPERIMENTAL"},{"description":"Patients receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.","label":"Arm II (Mosunetuzumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2032-03-31","type":"ESTIMATED"},"conditions":["Classic Follicular Lymphoma","Follicular Lymphoma With Unusual Cytological Features"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Mosunetuzumab","otherNames":["Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A","BTCT 4465A","BTCT-4465A","BTCT4465A","CD20/CD3 BiMAb BTCT4465A","Lunsumio","Mosunetuzumab-axgb","RG 7828","RG-7828","RG7828","RO7030816"],"type":"BIOLOGICAL"},{"name":"Positron Emission Tomography","otherNames":["Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","PT"],"type":"PROCEDURE"},{"name":"Rituximab","otherNames":["ABP 798","ABP-798","ABP798","BI 695500","BI-695500","BI695500","Blitzima","C2B8 Monoclonal Antibody","Chimeric Anti-CD20 Antibody","CT P10","CT-P10","CTP10","GP 2013","GP-2013","GP2013","IDEC 102","IDEC-102","IDEC-C2B8","IDEC-C2B8 Monoclonal Antibody","IDEC102","Ikgdar","Mabtas","MabThera","Monoclonal Antibody IDEC-C2B8","PF 05280586","PF-05280586","PF05280586","Riabni","Ritemvia","Rituxan","Rituximab ABBS","Rituximab ARRX","Rituximab Biosimilar ABP 798","Rituximab Biosimilar BI 695500","Rituximab Biosimilar CT-P10","Rituximab Biosimilar GB241","Rituximab Biosimilar GP2013","Rituximab Biosimilar IBI301","Rituximab Biosimilar JHL1101","Rituximab Biosimilar PF-05280586","Rituximab Biosimilar RTXM83","Rituximab Biosimilar SAIT101","Rituximab Biosimilar SIBP-02","rituximab biosimilar TQB2303","Rituximab PVVR","Rituximab-abbs","Rituximab-arrx","Rituximab-blit","Rituximab-pvvr","Rituximab-rite","Rituximab-rixa","Rituximab-rixi","Rixathon","Riximyo","RTXM 83","RTXM-83","RTXM83","Ruxience","Truxima"],"type":"BIOLOGICAL"},{"name":"Rituximab and Hyaluronidase Human","otherNames":["Rituxan Hycela","Rituximab Plus Hyaluronidase","Rituximab/Hyaluronidase","Rituximab/Hyaluronidase Human"],"type":"BIOLOGICAL"}],"last_update":"2026-10-28","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"3-year milestone progression free survival (PFS)","timeFrame":"From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 3 years"},{"measure":"PFS","timeFrame":"From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 10 years"}],"references":[],"start_date":{"date":"2024-10-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma","url":"https://clinicaltrials.gov/study/NCT06337318"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/s2308-nct06337318"}